Journal of Clinical Endocrinology & Metabolism, Vol 72, 367-373, Copyright © 1991 by Endocrine Society

ARTICLES

Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links

D Uebelhart, A Schlemmer, JS Johansen, E Gineyts, C Christiansen and PD Delmas
INSERM Unit 234, Hopital E. Herriot, Lyon, France.

Pyridinoline (Pyr) and deoxypyridinoline (D-Pyr) are two cross-links of collagen molecules that are present in the extracellular matrix and released during its degradation. In contrast to the wide distribution of collagen, Pyr is present in bone and cartilage, but not in significant amounts in other connective tissues, and D-Pyr appears to be specific for bone tissue. Therefore, the urinary excretion of Pyr and D-Pyr might be a sensitive marker of bone matrix degradation. Using a specific high pressure liquid chromatography assay we have measured Pyr and D-Pyr cross-links in a 24-h and a fasting urine sample in 60 early postmenopausal women and 19 premenopausal women matched for age. Menopause induced a 62% increase in Fu Pyr (49.8 +/- 18.7 vs. 30.8 +/- 8.0 pmol/mumol creatinine; P less than 0.001) and an 82% increase in Fu D-Pyr (8.2 +/- 3.4 vs. 4.5 +/- 1.4 pmol/mumol creatinine; P less than 0.001). In 20 postmenopausal women on hormone replacement therapy, urinary Pyr and D-Pyr returned to premenopausal levels within 6 months, contrasting with unchanged levels during placebo treatment. The 24-h excretion of Pyr and D-Pyr was significantly lower than the fasting excretion, but was similarly decreased after hormone replacement therapy. Pyr and D-Pyr excretion measured in the same urinary sample were highly correlated (r = 0.85 for fasting and 0.83 for 24-h sampling), but correlations between fasting and 24-h values were weak (D-Pyr, r = 0.30; Pyr, r = 0.29; P less than 0.05 for both). Correlations between urinary cross-links and other markers of bone turnover (Fu hydroxyproline/creatinine and plasma osteocalcin) were significant but low (Pyr vs. osteocalcin, r = 0.29, P less than 0.05; Pyr vs. hydroxyproline, r = 0/.34; P less than 0.01; D-Pyr vs. osteocalcin, r = 0.39; P less than 0.01), except for D-Pyr vs. hydroxyproline (r = 0.24; P = 0.07), suggesting that these markers reflect different events of bone metabolism. Finally, a single measurement of the fasting excretion, but not of the 24-h excretion, of cross-links was significantly correlated (Pyr, r = 0.34; P less than 0.05; D-Pyr, r = -0.46; P less than 0.01), with the subsequent spontaneous rate of bone loss assessed by repeated measurements of the radial bone mineral content in 37 postmenopausal women.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				M. Kleerekoper and P. Camacho Monitoring Osteoporosis Therapy Clin. Chem., December 1, 2005; 51(12): 2227 - 2228. [Full Text] [PDF]

				P. B. Rapuri, J. C. Gallagher, and G. Haynatzki Endogenous Levels of Serum Estradiol and Sex Hormone Binding Globulin Determine Bone Mineral Density, Bone Remodeling, the Rate of Bone Loss, and Response to Treatment with Estrogen in Elderly Women J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4954 - 4962. [Abstract] [Full Text] [PDF]

				B. Fohr, C. R. Dunstan, and M. J. Seibel Markers of Bone Remodeling in Metastatic Bone Disease J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5059 - 5075. [Abstract] [Full Text] [PDF]

				J. D. Ringe, A. Dorst, H. Faber, K. Ibach, and J. Preuss Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis Rheumatology, June 1, 2003; 42(6): 743 - 749. [Abstract] [Full Text] [PDF]

				M.-F. Hou, S.-B. Lin, S.-S. F. Yuan, L.-Y. Tsai, S.-M. Tsai, J.-S. Hsieh, and T.-J. Huang Diagnostic Value of Urine Deoxypyridinoline for Detecting Bone Metastases in Breast Cancer Patients Ann. Clin. Lab. Sci., January 1, 2003; 33(1): 55 - 61. [Abstract] [Full Text] [PDF]

				Y. Yamori, E. H. Moriguchi, T. Teramoto, A. Miura, Y. Fukui, K.-i. Honda, M. Fukui, Y. Nara, K. Taira, and Y. Moriguchi Soybean Isoflavones Reduce Postmenopausal Bone Resorption in Female Japanese Immigrants in Brazil: A Ten-Week Study J. Am. Coll. Nutr., December 1, 2002; 21(6): 560 - 563. [Abstract] [Full Text] [PDF]

				E Dogan and C Posaci Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women Postgrad. Med. J., December 1, 2002; 78(926): 727 - 731. [Abstract] [Full Text] [PDF]

				J. E. Compston Sex Steroids and Bone Physiol Rev, January 1, 2001; 81(1): 419 - 447. [Abstract] [Full Text] [PDF]

				S. L. Greenspan, H. N. Rosen, and R. A. Parker Early Changes in Serum N-Telopeptide and C-Telopeptide Cross-Linked Collagen Type 1 Predict Long-Term Response to Alendronate Therapy in Elderly Women J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3537 - 3540. [Abstract] [Full Text]

				A. Zittermann, I. Schwarz, K. Scheld, T. Sudhop, H. K. Berthold, K. von Bergmann, H. van der Ven, and P. Stehle Physiologic Fluctuations of Serum Estradiol Levels Influence Biochemical Markers of Bone Resorption in Young Women J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 95 - 101. [Abstract] [Full Text]

				M. Sarno, H. Powell, G. Tjersland, D. Schoendorfer, H. Harris, K. Adams, P. Ogata, and G. R. Warnick A Collection Method and High-Sensitivity Enzyme Immunoassay for Sweat Pyridinoline and Deoxypyridinoline Cross-Links Clin. Chem., September 1, 1999; 45(9): 1501 - 1509. [Abstract] [Full Text] [PDF]

				H. M. Perry III The Endocrinology of Aging Clin. Chem., August 1, 1999; 45(8): 1369 - 1376. [Abstract] [Full Text] [PDF]

				S. M Husain, Z. Mughal, G. Williams, K. Ward, C. S Smith, J. Dutton, and W. D Fraser Urinary excretion of pyridinium crosslinks in healthy 4-10 year olds Arch. Dis. Child., April 1, 1999; 80(4): 370 - 373. [Abstract] [Full Text]

				K. Lippuner, J.-P. Casez, F. F. Horber, and P. Jaeger Effects of Deflazacort Versus Prednisone on Bone Mass, Body Composition, and Lipid Profile: A Randomized, Double Blind Study in Kidney Transplant Patients J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3795 - 3802. [Abstract] [Full Text]

				J. C. Prior Perimenopause: The Complex Endocrinology of the Menopausal Transition Endocr. Rev., August 1, 1998; 19(4): 397 - 428. [Abstract] [Full Text] [PDF]

				H. N. Rosen, A. C. Moses, J. Garber, D. S. Ross, S. L. Lee, L. Ferguson, V. Chen, K. Lee, and S. L. Greenspan Randomized Trial of Pamidronate in Patients with Thyroid Cancer: Bone Density Is Not Reduced by Suppressive Doses of Thyroxine, But Is Increased by Cyclic Intravenous Pamidronate J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2324 - 2330. [Abstract] [Full Text]

				S. Kamel, P. Fardellone, B. Meddah, F. Lorget-Gondelmann, J. L. Sebert, and M. Brazier Response of several markers of bone collagen degradation to calcium supplementation in postmenopausal women with low calcium intake Clin. Chem., July 1, 1998; 44(7): 1437 - 1442. [Abstract] [Full Text] [PDF]

				S. Khosla, E. J. Atkinson, L. J. Melton III, and B. L. Riggs Effects of Age and Estrogen Status on Serum Parathyroid Hormone Levels and Biochemical Markers of Bone Turnover in Women: A Population-Based Study J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1522 - 1527. [Abstract] [Full Text] [PDF]

				M. J. Seibel and S. P. Robins Serum Undercarboxylated Osteocalcin and the Risk of Hip Fracture J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 717 - 718. [Full Text] [PDF]

				J. M. LANE, E. H. RILEY, and P. Z. WIRGANOWICZ Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Osteoporosis: Diagnosis and Treatment*{{dagger}} J. Bone Joint Surg. Am., April 1, 1996; 78(4): 618 - 32. [Full Text]